GlassScriptPhysician profile
Christopher T Arett
NPI 1972600559
$5,463.89
in general payments reported to CMS, 2019-2025
20 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $86.13 · 2021: $319 · 2022: $386 · 2023: $1,141 · 2024: $1,654 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098 · Honoraria: $250 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.30 |
| Honoraria | $250.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,018.34 | 2019-2025 | Spaceoar Vue System - 10ml, Lithovue, Rezum Generator |
| Teleflex LLC | $692.77 | 2021-2025 | Urolift, Barrigel |
| Calyxo, INC. | $530.80 | 2024-2025 | Cvac Aspiration System |
| Janssen Scientific Affairs, LLC | $361.03 | 2025 | Erleada |
| Myriad Genetic Laboratories, INC. | $288.32 | 2023-2025 | Prolaris |
| Procept Biorobotics Corporation | $278.38 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Cook Incorporated | $250.00 | 2023 | |
| Endo Pharmaceuticals INC. | $214.69 | 2019-2023 | Xiaflex, Aveed |
| Histosonics, INC. | $194.13 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $124.99 | 2025 | Adstiladrin |
| Innovation Technologies INC | $94.59 | 2023 | Irrisept |
| Edap Technomed INC | $58.00 | 2022 | |
| Karl Storz Endoscopy-America | $54.67 | 2024 | N.A. |
| Urogen Pharma, INC. | $47.15 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $43.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Janssen Biotech, INC. | $20.08 | 2019 | |
| Abbvie INC. | $17.61 | 2023 | Botox |
| Acerus Pharmaceuticals Corporation | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Arett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.